2022

TARPEYO® (budesonide) delayed release capsules became commercially available in the United States
NEFECON IN EUROPE, CHINA AND OTHER REGIONS
Following a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the European Commission (EC) approved KINPEYGO in Europe, granting Calliditas a conditional marketing authorization for adults with primary IgA nephropathy at risk of rapid disease progression
Chinese Regulatory authority National Medical Products Administration (NMPA) accepted Everest Medicines’ New Drug Application for NEFECON
ADVANCING PIPELINE WITH SETANAXIB
The first patient was randomized in pivotal phase 2b/3 TRANSFORM study in patients with primary biliary cholangitis (PBC)
The first patient was randomized in the Phase 2 Proof of Concept study in patients with Head and Neck cancer